Randomized, Double Blind, Placebo Controlled "First In-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 May 2015
At a glance
- Drugs PBF 509 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2012 Planned End Date changed to 31 Dec 2012, as reported in a Palobiofarma media release.
- 01 Nov 2012 Status changed from not yet recruiting to recruiting, according to a Palobiofarma media release.